Moreover, in the phase 1 study of diffuse-type tenosynovial giant-cell tumor (NCT01494688), anti-CSF1R antibody emactuzumab decreased tumor-infiltrating CD68/CD163+ macrophages and achieved pronounced activity (response rate: 71%) [276]. This evidence concerns the gene CSF1R and neoplasm.